Li Chen

The paper evaluates combinations of apoptosis pathway inhibitors with other agents in multi-cell type tumor spheroids to identify effective therapeutic strategies.

This study identifies LZK as a therapeutic target in HNSCC by showing its regulation of c-MYC and GOF p53, and demonstrates PROTAC-mediated degradation as a potential treatment.

This study develops a nanobody-enzyme fusion protein targeting PD-L1 and sialic acid, showing anti-tumor effects by modulating tumor-associated macrophages.